Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

NET

Cloudflare Inc

Apr 19 • 12:57PM ET

84.39

Dollar change -2.32
Percentage change -2.68	%

Technology • Software - Infrastructure • USA • NYSE

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VO VXF VUG VOT CIBR VGT IWP FDN IWF

Index	-	P/E	-	EPS (ttm)	-0.55	Insider Own	13.39%	Shs Outstand	298.09M	Perf Week	-9.99%
Market Cap	28.50B	Forward P/E	113.30	EPS next Y	0.74	Insider Trans	-5.89%	Shs Float	292.45M	Perf Month	-13.87%
Income	-183.95M	PEG	-	EPS next Q	0.13	Inst Own	74.92%	Short Float	3.90%	Perf Quarter	3.74%
Sales	1.30B	P/S	21.97	EPS this Y	19.22%	Inst Trans	-0.16%	Short Ratio	2.86	Perf Half Y	35.18%
Book/sh	2.26	P/B	37.33	EPS next Y	27.51%	ROA	-6.88%	Short Interest	11.40M	Perf Year	34.23%
Cash/sh	4.96	P/C	17.00	EPS next 5Y	-	ROE	-26.52%	52W Range	39.90 - 116.00	Perf YTD	1.36%
Dividend Est.	-	P/FCF	238.53	EPS past 5Y	-13.56%	ROI	-8.52%	52W High	-27.25%	Beta	1.15
Dividend TTM	-	Quick Ratio	3.50	Sales past 5Y	46.59%	Gross Margin	76.28%	52W Low	111.50%	ATR (14)	3.41
Dividend Ex-Date	-	Current Ratio	3.50	EPS Y/Y TTM	6.89%	Oper. Margin	-14.30%	RSI (14)	31.65	Volatility	3.55% 3.39%
Employees	3682	Debt/Eq	1.88	Sales Y/Y TTM	32.97%	Profit Margin	-14.19%	Recom	2.53	Target Price	101.35
Option/Short	Yes / Yes	LT Debt/Eq	1.83	EPS Q/Q	40.77%	Payout	-	Rel Volume	0.73	Prev Close	86.71
Sales Surprise	2.65%	EPS Surprise	23.86%	Sales Q/Q	31.95%	Earnings	May 02 AMC	Avg Volume	3.99M	Price	84.39
SMA20	-10.67%	SMA50	-12.48%	SMA200	11.00%	Trades		Volume	1,616,748	Change	-2.68%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-13-24	Downgrade	DZ Bank	Buy → Hold	$110
Feb-09-24	Resumed	Cantor Fitzgerald	Neutral	$100
Jan-18-24	Initiated	Bernstein	Mkt Perform	$85
Jan-17-24	Initiated	CapitalOne	Equal Weight	$83
Dec-15-23	Initiated	Susquehanna	Neutral	$75
Nov-21-23	Upgrade	Oppenheimer	Perform → Outperform
Sep-07-23	Initiated	BofA Securities	Underperform	$52
Aug-07-23	Downgrade	Guggenheim	Neutral → Sell	$50
Jun-05-23	Initiated	UBS	Sell	$55
May-05-23	Upgrade	Guggenheim	Sell → Neutral
Apr-19-23	Resumed	William Blair	Outperform
Feb-14-23	Initiated	Goldman	Sell	$51
Feb-07-23	Initiated	Loop Capital	Hold	$52
Jan-17-23	Downgrade	Guggenheim	Neutral → Sell	$36
Nov-28-22	Resumed	JP Morgan	Neutral	$42
Nov-02-22	Initiated	Macquarie	Neutral	$60
Oct-19-22	Resumed	Robert W. Baird	Outperform	$80
Oct-17-22	Upgrade	Wells Fargo	Equal Weight → Overweight	$62 → $65
Sep-22-22	Initiated	MoffettNathanson	Buy	$114
Sep-08-22	Initiated	Cantor Fitzgerald	Neutral	$65

Show Previous Ratings

Apr-18-24 06:00PM	Cloudflare (NET) Suffers a Larger Drop Than the General Market: Key Insights (Zacks)
09:00AM	Is Trending Stock Cloudflare, Inc. (NET) a Buy Now? (Zacks)
Apr-16-24 09:59AM	10 Best Password Managers in 2024 (Insider Monkey)
Apr-11-24 05:50PM	Cloudflare (NET) Rises Higher Than Market: Key Facts (Zacks)
04:45AM	Q4 Earnings Outperformers: Akamai (NASDAQ:AKAM) And The Rest Of The Software Development Stocks (StockStory)
04:46AM	Loading…
Apr-10-24 04:46AM	Winners And Losers Of Q4: Cloudflare (NYSE:NET) Vs The Rest Of The Software Development Stocks (StockStory)
Apr-09-24 08:59AM	Cloudflare (NET) & Booz Allen Team Up to Combat Cyber Threats (Zacks)
Apr-08-24 09:00AM	Cloudflare and Booz Allen Hamilton Now Delivering Rapid Incident Response for Enterprises Under Attack (Business Wire)
08:48AM	Cloudflare (NET) Buys Baselime to Enter Observability Market (Zacks)
Apr-07-24 05:35PM	Top 25 Biggest Internet Companies in the US (Insider Monkey)
Apr-06-24 08:32PM	20 Most Democratic Countries in Asia (Insider Monkey)
Apr-05-24 11:33AM	Cloudflare Enters Observability Market with Acquisition to Enhance Serverless Performance (Business Wire)
Apr-04-24 07:01PM	Cloudflare Inc (NET) CFO Thomas Seifert Sells 15,000 Shares (GuruFocus.com)
04:15PM	Cloudflare Announces Dates of First Quarter 2024 Financial Results and Investor Day (Business Wire)
Apr-03-24 10:03AM	Cloudflare (NET) Eases AI App Deployment With Workers AI Tool (Zacks)
09:00AM	Loading…
09:00AM	Is Most-Watched Stock Cloudflare, Inc. (NET) Worth Betting on Now? (Zacks)
Apr-02-24 07:00PM	Cloudflare Inc (NET) Chief Legal Officer Douglas Kramer Sells 3,000 Shares (GuruFocus.com)
09:00AM	Cloudflare Powers One-Click-Simple Global Deployment for AI Applications with Hugging Face (Business Wire)
08:22AM	Cloudflare, IBD Stock Of The Day, Upgrades Marketing Strategy Amid Artificial Intelligence Push (Investor's Business Daily)
07:45AM	Meta Platforms, AMD Lead 10 Stocks Showing This Bullish Action (Investor's Business Daily)
Apr-01-24 06:00PM	Cloudflare (NET) Registers a Bigger Fall Than the Market: Important Facts to Note (Zacks)
Mar-28-24 08:53AM	Fastly Stock Has 43% Upside, According to 1 Wall Street Analyst (Motley Fool)
06:00AM	3 Cybersecurity Stocks to Buy for the Next Bull Run: March 2024 (InvestorPlace)
Mar-26-24 09:00AM	Cloudflare Channel and Alliance Business Revenue Accelerates 174% Over Two Years and Expands with Additional Paths to Revenue, Program Awarded 5-Stars by CRN (Business Wire)
Mar-25-24 06:00PM	Why Cloudflare (NET) Dipped More Than Broader Market Today (Zacks)
Mar-20-24 09:00AM	Kyndryl and Cloudflare Announce Global Strategic Alliance to Drive Enterprise Network Transformation, Multi-Cloud Innovation, and Zero Trust Security (PR Newswire)
09:00AM	Cloudflare, Inc. (NET) is Attracting Investor Attention: Here is What You Should Know (Zacks)
06:25AM	Microsofts AI Security Bombshell: Is Copilot a $20B Game-Changer for MSFT Stock? (InvestorPlace)
04:52AM	Nvidia Led the First Phase of Artificial Intelligence (AI), but These 2 Growth Stocks Will Lead the Next Phases, According to a Wall Street Team (Motley Fool)
Mar-19-24 06:00PM	Cloudflare (NET) Rises Yet Lags Behind Market: Some Facts Worth Knowing (Zacks)
12:01AM	Loading…
12:01AM	Whats News: Business & Finance (The Wall Street Journal)
Mar-18-24 03:55PM	Tracking the Technical Support for: Cloudflare, Micron (CNBC TV)
01:28PM	Stephanie Cohen to join Cloudflare as another big-name executive departs Goldman Sachs (Fortune)
09:45AM	Here's Why Cloudflare (NET) is a Strong Growth Stock (Zacks)
08:51AM	UPDATE 3-Goldman Sachs veteran Stephanie Cohen resigns in latest senior exit (Reuters)
08:35AM	Stephanie Cohen Is Latest Senior Goldman Executive to Depart (The Wall Street Journal)
Mar-14-24 09:55AM	UPDATE 2-West, Central Africa see major internet outage with undersea cables down (Reuters)
09:40AM	West, Central Africa see major internet outage with undersea cables down (Reuters)
09:18AM	Internet disruption hits West and Central Africa, Netblocks and Cloudflare data shows (Reuters)
07:10AM	1 Reason to Sell Fastly Stock (Motley Fool)
Mar-13-24 08:15AM	Better Cloud Stock: Cloudflare vs. Fastly (Motley Fool)
05:45AM	2 No-Brainer Stocks to Buy With $100 Right Now (Motley Fool)
Mar-11-24 06:00PM	Why Cloudflare (NET) Dipped More Than Broader Market Today (Zacks)
07:59AM	Cloudflare (NET) Expands Presence in the Middle East Region (Zacks)
Mar-10-24 04:45AM	The Bull Market Is Official: 1 Monster Growth Stock Up 433% in 5 Years to Buy Now and Hold Long Term (Motley Fool)
Mar-09-24 05:15PM	Is Fastly Stock a Buy? (Motley Fool)
12:59PM	Edge Computing Market Size and Best Stocks To Buy (Insider Monkey)
04:45AM	The Artificial Intelligence (AI) Market Could Soar 820% by 2030: 2 AI Growth Stocks to Buy Now and Hold Long-Term (Motley Fool)
Mar-08-24 12:25PM	Here's Why Cloudflare Stock Climbed 25% in February (Motley Fool)
09:50AM	Here's Why Cloudflare (NET) is a Strong Momentum Stock (Zacks)
05:30AM	Cloudflare Doubles Down on Middle East; Expands Presence and Team to Support Growing Customer Demand (Business Wire)
Mar-07-24 08:07AM	Cloudflare (NET) Forays Into the Multicloud Networking Market (Zacks)
Mar-06-24 05:59PM	Cloudflare CEO Matthew Prince talks AI firewall and election cybersecurity (CNBC TV)
09:00AM	Cloudflare, Inc. (NET) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
09:00AM	Cloudflare Enters Multicloud Networking Market: Unlocks Simple, Secure Multicloud for Businesses (Business Wire)
Mar-05-24 11:54PM	Cloudflare Inc (NET) CFO Thomas Seifert Sells 15,000 Shares (GuruFocus.com)
01:22PM	AI Stock Cloudflare Offers Buy Point After 19% Surge. Here's Where To Buy. (Investor's Business Daily)
09:22AM	Cloudflare's (NET) Defensive.AI to Provide Customized Security (Zacks)
09:09AM	Could Fastly Stock Help You Become a Millionaire? (Motley Fool)
07:00AM	Want $1 Million in Retirement? Invest $50,000 in These 3 Stocks and Wait a Decade. (Motley Fool)
Mar-04-24 09:00AM	Cloudflare Firewall for AI Will Help Secure AI Applications, At Scale and For Free (Business Wire)
09:00AM	Cloudflare Expands Capabilities to Protect Organizations Against Emerging Threats with Defensive AI (Business Wire)
Mar-03-24 07:51AM	3 Under-the-Radar AI Stocks With Long-Term Growth Plans (Motley Fool)
02:00AM	GitLab (GTLB) To Report Earnings Tomorrow: Here Is What To Expect (StockStory)
Mar-01-24 05:50PM	Cloudflare (NET) Exceeds Market Returns: Some Facts to Consider (Zacks)
09:45AM	Why Cloudflare (NET) is a Top Growth Stock for the Long-Term (Zacks)
Feb-29-24 11:32PM	Cloudflare Inc (NET) Director Maria Eitel Sells 6,875 Shares (GuruFocus.com)
09:28AM	Jim Cramer's 10 New Stock Picks for March 2024 (Insider Monkey)
Feb-28-24 06:15AM	Missed Out on Nvidia? Buy This Under-the-Radar AI Inference Play Instead (Motley Fool)
05:18AM	1 Wall Street Analyst Raises Cloudflare's Price Target by 55%: Here's Why They're Right. (Motley Fool)
Feb-26-24 09:19PM	Lightning Round: Cloudflare is a 'must hold onto' stock, says Jim Cramer (CNBC TV)
Feb-25-24 06:30AM	Is Palo Alto Networks a Buy on Its Post-Earnings Plunge? (Motley Fool)
Feb-23-24 04:23AM	Do You think Cloudflare (NET) is Gaining Market Share? (Insider Monkey)
Feb-22-24 04:35PM	3 AI-Exposed Stocks to Grab Before Wall Street Catches On (InvestorPlace)
11:31AM	3 Cybersecurity Stocks That Could Be Multibaggers in the Making: February Edition (InvestorPlace)
09:00AM	Investors Heavily Search Cloudflare, Inc. (NET): Here is What You Need to Know (Zacks)
12:02AM	Decoding Cloudflare Inc (NET): A Strategic SWOT Insight (GuruFocus.com)
Feb-21-24 11:51PM	Cloudflare Inc CFO Thomas Seifert Sells 27,901 Shares (GuruFocus.com)
02:30PM	3 Metaverse Stocks to Turn $250,000 Into $1 Million: February 2024 (InvestorPlace)
11:00AM	Heard on the Street: Palo Alto Networks' Earnings Cast a Pall on Cybersecurity (The Wall Street Journal)
09:50AM	Here's Why Cloudflare (NET) is a Strong Momentum Stock (Zacks)
05:30AM	Cloudflare Stock: Buy, Sell, or Hold? (Motley Fool)
Feb-18-24 02:00PM	This Super Artificial Intelligence (AI) Stock Could Be at the Beginning of a Terrific Bull Run (Motley Fool)
07:28AM	Up Over 30% So Far in 2024, Is Cloudflare Stock a Buy Right Now? (Motley Fool)
Feb-17-24 06:15AM	3 High-Flying AI Stocks Investors Should Stop Buying (for Now) (Motley Fool)
05:07AM	Is It Too Late to Buy Cloudflare Stock? (Motley Fool)
Feb-16-24 01:55PM	17 Fastest growing B2B SaaS Companies (Insider Monkey)
06:30AM	Cloudflare Jumps 20% in a Day: Is It Still a Buy? (Motley Fool)
Feb-15-24 07:14AM	The Next Magnificent 7 Stock? 7 Growth Plays That Investors Shouldnt Ignore (InvestorPlace)
05:38AM	Could Cloudflare Stock Help You Become a Millionaire? (Motley Fool)
Feb-14-24 04:00PM	3 Revolutionary Companies on the Brink of Growth (InvestorPlace)
08:37AM	3 Millionaire-Maker Artificial Intelligence (AI) Stocks (Motley Fool)
05:48AM	Plaid names Cloudflare vet as its first president ahead of eventual IPO (Banking Dive)
Feb-13-24 12:15PM	Why Microsoft, Cloudflare, and Palo Alto Networks Stocks Just Dropped (Motley Fool) -5.43%
09:40AM	Is Cloudflare (NET) Outperforming Other Computer and Technology Stocks This Year? (Zacks)
Feb-12-24 02:02AM	Akamai Earnings: What To Look For From AKAM (StockStory)
Feb-11-24 09:37AM	Straight From the CEO's Mouth: How 3 Innovators Are Shaping the Future of AI (Motley Fool)
Feb-10-24 09:02AM	Analysts unveil new Cloudflare stock price target after earnings (TheStreet)
Feb-09-24 04:49PM	Expedia, Cloudflare, Affirm, PepsiCo, AMC Networks, Pinterest, Take-Two, and More of Todays Stock Market Movers (Barrons.com) +19.50%
03:33PM	Why Datadog, Snowflake, and Other Cloud Stocks Rallied on Friday (Motley Fool)

Cloudflare, Inc. engages in the provision of cloud-based services to secure websites. It offers various products for performance and reliability, video streaming and delivery, advanced security, insights, Cloudflare for developers, domain registration and Cloudflare marketplace. It operates through United States and Rest of the World geographical segments. The company was founded by Matthew Prince, Michelle Zatlyn and Lee Holloway in July 2009 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Zatlyn Michelle	President and COO	Apr 18 '24	Sale	87.07	18,955	1,650,463	19,615	Apr 18 08:14 PM
Zatlyn Michelle	President and COO	Apr 17 '24	Sale	90.10	19,505	1,757,371	19,615	Apr 18 08:14 PM
Ledbetter Carl	Director	Apr 17 '24	Sale	90.39	8,029	725,769	1,214,830	Apr 18 06:46 PM
Zatlyn Michelle	President and COO	Apr 16 '24	Sale	89.69	25,640	2,299,578	19,615	Apr 18 08:14 PM
Prince Matthew	CEO & Chair of the Board	Apr 11 '24	Sale	95.29	52,384	4,991,826	0	Apr 11 08:22 PM
Prince Matthew	CEO & Chair of the Board	Apr 10 '24	Sale	94.94	52,384	4,973,089	0	Apr 11 08:22 PM
Ledbetter Carl	Director	Apr 10 '24	Sale	94.37	44,154	4,166,635	1,222,859	Apr 11 06:42 PM
Prince Matthew	CEO & Chair of the Board	Apr 09 '24	Sale	96.04	52,384	5,030,854	0	Apr 11 08:22 PM
SEIFERT THOMAS J	CHIEF FINANCIAL OFFICER	Apr 03 '24	Sale	94.91	15,000	1,423,642	338,469	Apr 04 03:31 PM
Ledbetter Carl	Director	Apr 03 '24	Sale	94.05	7,991	751,566	1,267,013	Apr 04 03:35 PM
Kramer Douglas James	CHIEF LEGAL OFFICER	Apr 01 '24	Sale	97.16	3,000	291,480	205,238	Apr 02 04:59 PM
Ledbetter Carl	Director	Mar 27 '24	Sale	100.16	9,993	1,000,916	1,275,004	Mar 28 04:06 PM
Ledbetter Carl	Director	Mar 20 '24	Sale	95.08	7,968	757,605	1,284,997	Mar 20 06:59 PM
SEIFERT THOMAS J	Chief Financial Officer	Mar 15 '24	Sale	91.77	95,000	8,718,453	0	Mar 19 04:10 PM
SEIFERT THOMAS J	Chief Financial Officer	Mar 15 '24	Sale	91.77	15,000	1,376,562	338,469	Mar 19 04:10 PM
Prince Matthew	CEO & Chair of the Board	Mar 14 '24	Sale	94.25	52,384	4,937,165	12,183	Mar 14 08:11 PM
Prince Matthew	CEO & Chair of the Board	Mar 13 '24	Sale	96.83	52,384	5,072,501	12,183	Mar 14 08:11 PM
Ledbetter Carl	Director	Mar 13 '24	Sale	96.43	44,099	4,252,598	1,292,965	Mar 14 04:29 PM
Prince Matthew	CEO & Chair of the Board	Mar 12 '24	Sale	96.66	52,384	5,063,274	12,183	Mar 14 08:11 PM
Zatlyn Michelle	President and COO	Mar 08 '24	Sale	101.02	25,640	2,590,144	19,615	Mar 08 07:20 PM
Zatlyn Michelle	President and COO	Mar 07 '24	Sale	98.72	25,640	2,531,290	19,615	Mar 08 07:20 PM
Zatlyn Michelle	President and COO	Mar 06 '24	Sale	97.96	25,640	2,511,730	19,615	Mar 08 07:20 PM
Ledbetter Carl	Director	Mar 06 '24	Sale	98.35	8,022	788,947	1,337,064	Mar 07 06:14 PM
SEIFERT THOMAS J	CHIEF FINANCIAL OFFICER	Mar 04 '24	Sale	99.87	15,000	1,498,088	338,469	Mar 05 06:12 PM
Kramer Douglas James	CHIEF LEGAL OFFICER	Mar 04 '24	Sale	99.64	3,000	298,920	205,238	Mar 05 06:15 PM
Eitel Maria S	Director	Feb 29 '24	Sale	98.51	6,875	677,248	23,513	Feb 29 05:56 PM
Ledbetter Carl	Director	Feb 28 '24	Sale	96.35	10,010	964,484	1,345,086	Feb 29 05:19 PM
Prince Matthew	CEO & Chair of the Board	Feb 23 '24	Sale	98.75	52,384	5,173,032	12,183	Feb 23 08:19 PM
Prince Matthew	CEO & Chair of the Board	Feb 22 '24	Sale	99.17	52,384	5,194,859	12,183	Feb 23 08:19 PM
Prince Matthew	CEO & Chair of the Board	Feb 21 '24	Sale	94.59	52,384	4,955,066	12,183	Feb 23 08:19 PM
Ledbetter Carl	Director	Feb 21 '24	Sale	94.74	7,970	755,054	1,355,096	Feb 21 04:32 PM
SEIFERT THOMAS J	CHIEF FINANCIAL OFFICER	Feb 20 '24	Sale	96.56	27,901	2,694,074	338,469	Feb 21 07:52 PM
Zatlyn Michelle	President and COO	Feb 20 '24	Sale	96.32	25,640	2,469,563	0	Feb 20 08:08 PM
Zatlyn Michelle	President and COO	Feb 16 '24	Sale	99.32	158,524	15,744,242	0	Feb 20 08:08 PM
Zatlyn Michelle	President and COO	Feb 15 '24	Sale	101.17	277,376	28,063,427	38,545	Feb 20 08:08 PM
Ledbetter Carl	Director	Feb 14 '24	Sale	100.16	44,220	4,428,953	1,363,066	Feb 15 08:43 PM
SEIFERT THOMAS J	Chief Financial Officer	Feb 09 '24	Sale	110.11	50,000	5,505,730	366,465	Feb 12 08:10 PM
Kramer Douglas James	CHIEF LEGAL OFFICER	Feb 09 '24	Sale	110.08	6,000	660,480	216,114	Feb 13 05:46 PM
Ledbetter Carl	Director	Feb 08 '24	Sale	86.92	39,671	3,448,080	1,407,286	Feb 09 05:22 PM
Ledbetter Carl	Director	Feb 07 '24	Sale	81.42	7,962	648,272	1,446,957	Feb 09 05:22 PM
SEIFERT THOMAS J	Chief Financial Officer	Feb 02 '24	Sale	81.87	15,000	1,227,981	366,465	Feb 05 05:28 PM
Kramer Douglas James	Chief Legal Officer	Feb 01 '24	Sale	79.60	3,000	238,800	216,114	Feb 02 04:47 PM
Ledbetter Carl	Director	Jan 31 '24	Sale	80.91	10,031	811,563	1,454,919	Feb 01 05:14 PM
Ledbetter Carl	Director	Jan 24 '24	Sale	85.06	7,982	678,911	1,464,950	Jan 24 04:26 PM
Ledbetter Carl	Director	Jan 22 '24	Sale	86.88	66,384	5,767,734	1,472,932	Jan 24 04:26 PM
Zatlyn Michelle	President and COO	Jan 19 '24	Sale	78.68	12,820	1,008,681	0	Jan 19 08:05 PM
SEIFERT THOMAS J	Chief Financial Officer	Jan 18 '24	Sale	77.73	15,000	1,165,979	243,495	Jan 19 06:49 PM
Zatlyn Michelle	President and COO	Jan 18 '24	Sale	78.49	12,820	1,006,271	0	Jan 19 08:05 PM
Ledbetter Carl	Director	Jan 17 '24	Sale	76.03	30,214	2,297,060	1,539,316	Jan 17 06:20 PM
Zatlyn Michelle	President and COO	Jan 17 '24	Sale	76.15	12,820	976,282	0	Jan 19 08:05 PM
Ledbetter Carl	Director	Jan 10 '24	Sale	82.35	7,970	656,368	1,569,530	Jan 11 04:23 PM
Prince Matthew	CEO & Chair of the Board	Jan 09 '24	Sale	80.80	52,384	4,232,428	0	Jan 09 07:04 PM
Prince Matthew	CEO & Chair of the Board	Jan 08 '24	Sale	78.78	52,384	4,127,051	0	Jan 09 07:04 PM
Prince Matthew	CEO & Chair of the Board	Jan 05 '24	Sale	76.80	52,384	4,023,072	0	Jan 09 07:04 PM
SEIFERT THOMAS J	Chief Financial Officer	Jan 03 '24	Sale	76.80	15,000	1,152,010	243,495	Jan 03 07:30 PM
Ledbetter Carl	Director	Jan 03 '24	Sale	76.22	10,047	765,753	1,577,500	Jan 03 07:27 PM
Kramer Douglas James	General Counsel	Jan 02 '24	Sale	81.43	3,000	244,290	154,629	Jan 03 05:26 PM
Ledbetter Carl	Director	Dec 27 '23	Sale	86.48	9,620	831,909	1,587,547	Dec 28 04:07 PM
Ledbetter Carl	Director	Dec 20 '23	Sale	84.59	30,384	2,570,069	1,597,167	Dec 21 04:39 PM
Ledbetter Carl	Director	Dec 19 '23	Sale	86.76	4,296	372,707	1,627,551	Dec 21 04:39 PM
SEIFERT THOMAS J	Chief Financial Officer	Dec 18 '23	Sale	84.86	15,000	1,272,851	243,495	Dec 19 04:32 PM
SEIFERT THOMAS J	Chief Financial Officer	Dec 13 '23	Sale	80.21	34,329	2,753,546	243,495	Dec 14 04:51 PM
Ledbetter Carl	Director	Dec 13 '23	Sale	78.97	7,961	628,655	1,631,847	Dec 15 04:48 PM
Zatlyn Michelle	President and COO	Dec 08 '23	Sale	77.02	12,820	987,460	0	Dec 08 07:43 PM
Zatlyn Michelle	President and COO	Dec 07 '23	Sale	76.46	12,820	980,171	0	Dec 08 07:43 PM
Zatlyn Michelle	President and COO	Dec 06 '23	Sale	78.46	12,820	1,005,913	0	Dec 08 07:43 PM
Ledbetter Carl	Director	Dec 06 '23	Sale	77.98	10,027	781,916	1,639,808	Dec 07 05:58 PM
SEIFERT THOMAS J	Chief Financial Officer	Dec 06 '23	Sale	80.00	400	32,000	243,495	Dec 08 04:18 PM
Prince Matthew	CEO & Chair of the Board	Dec 05 '23	Sale	78.21	52,384	4,097,152	10,723	Dec 05 07:59 PM
Prince Matthew	CEO & Chair of the Board	Dec 04 '23	Sale	79.30	52,384	4,153,932	10,723	Dec 05 07:59 PM
SEIFERT THOMAS J	Chief Financial Officer	Dec 04 '23	Sale	79.70	30,271	2,412,690	243,495	Dec 05 06:58 PM
Prince Matthew	CEO & Chair of the Board	Dec 01 '23	Sale	77.49	52,384	4,059,178	10,723	Dec 05 07:59 PM
Kramer Douglas James	General Counsel	Dec 01 '23	Sale	77.77	3,000	233,310	154,629	Dec 04 04:36 PM
Zatlyn Michelle	President and COO	Nov 29 '23	Sale	76.35	12,820	978,848	0	Nov 29 06:39 PM
Ledbetter Carl	Director	Nov 29 '23	Sale	76.19	8,034	612,075	1,649,835	Nov 30 04:09 PM
Zatlyn Michelle	President and COO	Nov 28 '23	Sale	73.58	12,820	943,294	0	Nov 29 06:39 PM
Zatlyn Michelle	President and COO	Nov 27 '23	Sale	73.21	12,820	938,513	0	Nov 29 06:39 PM
Ledbetter Carl	Director	Nov 22 '23	Sale	74.37	30,251	2,249,770	1,657,869	Nov 27 04:04 PM
SANDELL SCOTT D	Director	Nov 20 '23	Sale	73.17	211,534	15,477,312	0	Nov 22 04:55 PM
SEIFERT THOMAS J	Chief Financial Officer	Nov 17 '23	Sale	72.13	16,901	1,219,023	243,495	Nov 20 04:30 PM
Prince Matthew	CEO & Chair of the Board	Nov 15 '23	Sale	71.22	52,384	3,730,913	0	Nov 15 07:49 PM
Ledbetter Carl	Director	Nov 15 '23	Sale	70.85	8,008	567,376	1,688,120	Nov 16 04:38 PM
Prince Matthew	CEO & Chair of the Board	Nov 14 '23	Sale	68.80	52,384	3,604,070	0	Nov 15 07:49 PM
Prince Matthew	CEO & Chair of the Board	Nov 13 '23	Sale	63.48	52,384	3,325,473	0	Nov 15 07:49 PM
Ledbetter Carl	Director	Nov 08 '23	Sale	65.63	10,050	659,573	1,696,128	Nov 09 04:16 PM
SEIFERT THOMAS J	Chief Financial Officer	Nov 03 '23	Sale	63.18	15,000	947,641	253,352	Nov 06 04:15 PM
Ledbetter Carl	Director	Nov 03 '23	Sale	61.25	11,206	686,332	1,706,178	Nov 06 04:10 PM
Ledbetter Carl	Director	Nov 01 '23	Sale	55.99	8,039	450,091	1,717,384	Nov 02 06:51 PM
Kramer Douglas James	General Counsel	Nov 01 '23	Sale	56.48	3,000	169,440	159,470	Nov 02 06:48 PM
Ledbetter Carl	Director	Oct 25 '23	Sale	58.04	19,057	1,106,056	1,725,423	Oct 26 05:34 PM
SEIFERT THOMAS J	Chief Financial Officer	Oct 18 '23	Sale	63.03	15,000	945,432	253,352	Oct 19 06:53 PM
Zatlyn Michelle	President and COO	Oct 18 '23	Sale	63.90	12,820	819,220	0	Oct 18 09:10 PM
Ledbetter Carl	Director	Oct 18 '23	Sale	63.99	8,037	514,301	1,744,480	Oct 19 06:47 PM
Zatlyn Michelle	President and COO	Oct 17 '23	Sale	62.95	12,820	806,975	0	Oct 18 09:10 PM
Zatlyn Michelle	President and COO	Oct 16 '23	Sale	62.00	12,820	794,862	0	Oct 18 09:10 PM
Ledbetter Carl	Director	Oct 11 '23	Sale	66.54	10,016	666,462	1,752,517	Oct 12 04:59 PM
Prince Matthew	CEO & Chair of the Board	Oct 06 '23	Sale	61.29	52,384	3,210,563	0	Oct 06 08:13 PM
Prince Matthew	CEO & Chair of the Board	Oct 05 '23	Sale	57.73	52,384	3,023,992	0	Oct 06 08:13 PM
Prince Matthew	CEO & Chair of the Board	Oct 04 '23	Sale	59.02	52,384	3,091,842	0	Oct 06 08:13 PM
Ledbetter Carl	Director	Oct 04 '23	Sale	59.09	7,985	471,859	1,762,533	Oct 05 04:59 PM

Open in Screener

ADAP

Adaptimmune Therapeutics Plc ADR

Apr 19 • 12:57PM ET

1.00

Dollar change +0.11
Percentage change 11.87	%

Healthcare • Biotechnology • United Kingdom • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

ADAP Adaptimmune Therapeutics Plc ADR daily Stock Chart

Index	-	P/E	-	EPS (ttm)	-0.52	Insider Own	11.91%	Shs Outstand	227.17M	Perf Week	-13.36%
Market Cap	228.31M	Forward P/E	-	EPS next Y	-0.59	Insider Trans	-0.61%	Shs Float	200.12M	Perf Month	-24.44%
Income	-114.08M	PEG	-	EPS next Q	-0.15	Inst Own	62.38%	Short Float	1.60%	Perf Quarter	43.04%
Sales	60.69M	P/S	3.76	EPS this Y	-467.56%	Inst Trans	-0.52%	Short Ratio	1.61	Perf Half Y	71.27%
Book/sh	0.17	P/B	5.78	EPS next Y	-15.85%	ROA	-37.31%	Short Interest	3.20M	Perf Year	-33.44%
Cash/sh	0.65	P/C	1.55	EPS next 5Y	1.00%	ROE	-187.96%	52W Range	0.42 - 2.05	Perf YTD	26.73%
Dividend Est.	-	P/FCF	-	EPS past 5Y	10.30%	ROI	-192.17%	52W High	-50.98%	Beta	2.50
Dividend TTM	-	Quick Ratio	2.85	Sales past 5Y	134.88%	Gross Margin	83.77%	52W Low	139.29%	ATR (14)	0.13
Dividend Ex-Date	-	Current Ratio	2.85	EPS Y/Y TTM	48.98%	Oper. Margin	-250.53%	RSI (14)	34.43	Volatility	12.49% 9.47%
Employees	449	Debt/Eq	0.64	Sales Y/Y TTM	123.93%	Profit Margin	-187.98%	Recom	2.14	Target Price	3.50
Option/Short	Yes / Yes	LT Debt/Eq	0.50	EPS Q/Q	-18.55%	Payout	-	Rel Volume	1.01	Prev Close	0.90
Sales Surprise	-99.11%	EPS Surprise	75.76%	Sales Q/Q	-97.90%	Earnings	Mar 06 BMO	Avg Volume	1.99M	Price	1.00
SMA20	-23.53%	SMA50	-27.92%	SMA200	12.62%	Trades		Volume	1,114,611	Change	11.87%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-24-23	Initiated	Bryan Garnier	Buy	$3.60
Jan-03-23	Upgrade	Guggenheim	Neutral → Buy	$5
Nov-09-22	Upgrade	Mizuho	Neutral → Buy	$9
May-28-21	Initiated	Barclays	Underweight	$4
Apr-22-20	Initiated	Mizuho	Neutral	$3
Aug-02-19	Downgrade	Guggenheim	Buy → Neutral
May-31-19	Initiated	ROTH Capital	Buy
May-30-19	Resumed	Citigroup	Buy
May-07-19	Downgrade	SVB Leerink	Outperform → Mkt Perform	$12 → $5
Mar-17-17	Initiated	Wells Fargo	Market Perform
Oct-24-16	Downgrade	BofA/Merrill	Neutral → Underperform
Sep-30-16	Initiated	Raymond James	Outperform	$16
Feb-25-16	Initiated	Citigroup	Buy	$15
Jun-01-15	Initiated	Leerink Partners	Outperform	$24
Jun-01-15	Initiated	Guggenheim	Buy
Jun-01-15	Initiated	BofA/Merrill	Neutral

Show Previous Ratings

Apr-15-24 02:12PM	Adaptimmune (ADAP) Down on End of Collaboration With Roche (Zacks) -9.48%
Apr-12-24 08:00AM	Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated (Newsfile) -10.08%
05:37AM	Roche, Adaptimmune part ways on cell therapy research (BioPharma Dive)
Mar-27-24 07:30PM	Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet (Newsfile)
Mar-07-24 01:42PM	Adaptimmune Therapeutics PLC Reports Q4 and Full Year 2023 Financial Results (GuruFocus.com)
08:24AM	Loading…
08:24AM	Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-06-24 12:52PM	ADAP Stock Earnings: Adaptimmune Therapeutics Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace) +17.12%
07:00AM	Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates (Newsfile)
Feb-27-24 08:00AM	Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise (Newsfile)
Feb-21-24 04:00PM	Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024 (Newsfile) +19.05%
Feb-16-24 03:57AM	15 Top Performing European Stocks So Far in 2024 (Insider Monkey)
Feb-13-24 06:15PM	Adaptimmune Therapeutics PLC (ADAP) Stock Moves -1.24%: What You Should Know (Zacks)
Jan-31-24 04:44PM	Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review (Newsfile) +9.74%
Jan-30-24 01:02PM	Baillie Gifford Increases Stake in Adaptimmune Therapeutics PLC (GuruFocus.com) +10.18%
Jan-16-24 11:17AM	Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why (Zacks) -13.72%
07:37AM	Loading…
Jan-04-24 07:37AM	Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference (Newsfile) +12.40%
Dec-06-23 07:00AM	Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma (Newsfile)
Nov-30-23 10:52AM	Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy IND (Zacks)
Nov-29-23 08:00AM	Adaptimmune Receives Transfer of IND for Lete-cel Program (Newsfile) +11.66%
Nov-13-23 09:35AM	Adaptimmune Therapeutics PLC (ADAP) Loses -28.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
08:35AM	Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 07:30AM	Adaptimmune Reports Third Quarter Financial Results and Business Update (Newsfile) -5.57%
07:05AM	Adaptimmune Selects ADP-600 as Clinical Candidate for Best-in Class PRAME Strategy (Newsfile)
Nov-07-23 06:15PM	Adaptimmune Therapeutics PLC (ADAP) Surpasses Market Returns: Some Facts Worth Knowing (Zacks)
Oct-31-23 08:00AM	Adaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS (Newsfile)
08:00AM	Adaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control (Newsfile)
Oct-27-23 06:15PM	Adaptimmune Therapeutics PLC (ADAP) Suffers a Larger Drop Than the General Market: Key Insights (Zacks)
Oct-25-23 08:06AM	Adaptimmune to Report Q3 2023 Financial and Business Updates on Wednesday, November 8, 2023 (Newsfile)
Oct-23-23 04:15AM	Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO (Newsfile) +6.25%
Sep-11-23 08:00AM	Dr. Karen Chagin Joins Adaptimmune as Senior Vice President of Early-Stage Development (Newsfile) +8.81%
07:29AM	Loading…
Aug-09-23 07:29AM	Adaptimmune Reports Second Quarter Financial Results and Business Update (Newsfile)
Aug-03-23 01:24PM	Adaptimmune to Report Q2 2023 Financial and Business Updates on Wednesday, August 9, 2023 (Newsfile)
Jul-28-23 12:30PM	Adaptimmune (ADAP) to Report Q2 Earnings: What's in the Cards? (Zacks)
Jul-20-23 07:28AM	Investors in Adaptimmune Therapeutics (NASDAQ:ADAP) from five years ago are still down 90%, even after 12% gain this past week (Simply Wall St.) -10.10%
Jul-16-23 08:18PM	Arcturus Therapeutics (ARCT) Surges 15.0%: Is This an Indication of Further Gains? (Zacks)
Jun-29-23 09:18AM	Reata's (RETA) Skyclarys PAS Gets FDA Nod, Stock Rises 7% (Zacks)
Jun-26-23 11:23AM	AbbVie (ABBV) Gets CHMP Positive Opinion for Atogepant Approval (Zacks)
11:15AM	Novo Nordisk (NVO) Posts Upbeat Once-Weekly Insulin Icodec Data (Zacks)
Jun-23-23 09:15AM	Horizon's (HZNP) Tepezza Study in Japan for TED Meets Goal (Zacks)
Jun-22-23 09:40AM	Amgen's (AMGN) Blincyto sBLA Gets FDA Nod in Treating Leukemia (Zacks)
Jun-19-23 10:18AM	GSK Announces Extension of FDA Review for Rare Blood Therapy (Zacks)
Jun-16-23 08:39AM	Iovance (IOVA) Updates on Combo Drug in Advanced Melanoma Study (Zacks)
Jun-15-23 09:43AM	Lava (LVTX) Discontinues Hematological Tumor Study, Shares Fall (Zacks)
08:18AM	IO Biotech (IOBT) Down Despite Positive Update on Melanoma Study (Zacks)
Jun-13-23 10:14AM	AstraZeneca (AZN) Breast Cancer Combo Drug Gets Priority Review (Zacks)
Jun-12-23 10:00AM	Editas (EDIT) Posts Upbeat Initial Data From SCD & TDT Studies (Zacks) +5.33%
09:48AM	AstraZeneca (AZN) & Quell to Co-Develop Autoimmune Cell Therapies (Zacks)
Jun-09-23 10:52AM	Merck's (MRK) Keytruda for Liver Cancer to Undergo FDA Review (Zacks)
Jun-06-23 06:50AM	Dr. Reddy's (RDY) Meets Goals in Actemra Biosimilar Study (Zacks)
Jun-05-23 11:40AM	Novo Nordisk (NVO) Gears Up to Acquire BIOCORP for 154M Euros (Zacks)
10:22AM	Bristol Myers (BMY) Announces Upbeat Data From NSCLC Study (Zacks)
Jun-01-23 03:29PM	Adaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company (Newsfile) +6.86%
May-30-23 09:35AM	Down -22.38% in 4 Weeks, Here's Why You Should You Buy the Dip in Adaptimmune Therapeutics PLC (ADAP) (Zacks)
May-25-23 05:00PM	Adaptimmune Announces 70% of People with Advanced Synovial Sarcoma Who Respond to Afami-cel are Alive Two Years Post-Treatment; Data from Cohort 1 of SPEARHEAD-1 to be Presented at ASCO (Newsfile)
May-12-23 07:29AM	Adaptimmune Reports First Quarter Financial Results and Business Update (Newsfile)
May-09-23 06:43AM	Is Adaptimmune Therapeutics (NASDAQ:ADAP) In A Good Position To Invest In Growth? (Simply Wall St.)
May-05-23 05:00AM	Zacks.com featured highlights Sweetgreen, Adaptimmune Therapeutics, Owl Rock Capital, MACOM Technology Solutions and Equity Commonwealth (Zacks)
Apr-28-23 12:00PM	Adaptimmune to Report Q1 2023 Financial and Business Updates on Friday, May 12, 2023 (Newsfile)
Apr-18-23 11:49AM	Adaptimmune Therapeutics plc (NASDAQ:ADAP) Looks Inexpensive But Perhaps Not Attractive Enough (Simply Wall St.)
Apr-12-23 10:42AM	Adaptimmune (ADAP) Up 7%, Gets T-Cell Programs Rights From GSK (Zacks)
Apr-11-23 12:13PM	Why Shares of Adaptimmune Therapeutics Jumped Tuesday (Motley Fool) +7.08%
08:00AM	Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune (Newsfile)
Mar-08-23 07:14AM	Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2022 Earnings Call Transcript (Insider Monkey)
05:23AM	News Flash: Analysts Just Made A Huge Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecasts (Simply Wall St.)
Mar-06-23 01:08PM	Adaptimmune Agrees To Merge With Another Cell Therapy Focused Company (Benzinga) -25.00%
06:30AM	Adaptimmune Reports Fourth-Quarter and Full Year Financial Results and Business Update (Newsfile)
06:00AM	Adaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors (Newsfile)
Feb-22-23 08:00AM	Adaptimmune to Report Q4 and Full Year 2022 Financial and Business Updates on Monday, March 6, 2023 (Newsfile)
Feb-16-23 08:00AM	Adaptimmune Announces Changes to Board of Directors (Newsfile)
Jan-09-23 08:00AM	Publication of Data from Adaptimmune's Completed Phase 1 Trial with Afami-cel in Nature Medicine Demonstrating an Acceptable Safety Profile and Encouraging Responses in Synovial Sarcoma (Newsfile) -9.95%
Jan-08-23 07:06AM	Even after rising 48% this past week, Adaptimmune Therapeutics (NASDAQ:ADAP) shareholders are still down 72% over the past five years (Simply Wall St.)
Dec-28-22 06:51AM	Mesa Labs and Eldorado Gold have been highlighted as Zacks Bull and Bear of the Day (Zacks) -5.30%
Dec-27-22 09:05AM	3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying (Zacks)
Dec-23-22 01:20PM	Adaptimmune Announces Initiation of Biologics License Application (BLA) Submission for Afami-cel, Its First-Gen Engineered TCR T-cell Therapy targeting MAGE-A4, For the Treatment of Synovial Sarcoma (Newsfile)
Dec-10-22 09:02AM	Hedge funds investors may adopt severe steps after Adaptimmune Therapeutics plc's (NASDAQ:ADAP) latest 20% drop adds to a year losses (Simply Wall St.)
Nov-18-22 08:00AM	Data from Cohort 1 of SPEARHEAD-1 Trial at CTOS Continue to Support BLA Submission for Afami-cel in Synovial Sarcoma - Response Rate and Durability Remain Consistent (Newsfile)
Nov-13-22 07:28AM	New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP) (Simply Wall St.)
Nov-11-22 10:52AM	Lab notes: Adaptimmune to reduce workforce; NRx completes $11M debt financing (American City Business Journals) +13.06%
Nov-10-22 06:03AM	Adaptimmune Therapeutics Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.) +5.71%
Nov-08-22 03:11PM	Why Adaptimmune Therapeutics Stock Is Glowing Green Today (Motley Fool) +25.30%
09:41AM	Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Strong Position To Grow Its Business (Simply Wall St.)
07:30AM	Adaptimmune Reports Third-Quarter Financial Results and Business Update (Newsfile)
07:00AM	Adaptimmune Reports Increased Response Rate and Durability of Response in Its Phase 1 SURPASS trial; ORR Now 52% Across Ovarian, Urothelial, and Head & Neck Cancers (Newsfile)
Oct-27-22 12:27PM	Adaptimmune to Report Q3 2022 Financial and Business Updates on Tuesday, November 8, 2022 (Newsfile)
Oct-25-22 11:12AM	GSK Transfers Cell Therapy Program Rights To Adaptimmune, Terminates Second Cell Therapy Pact In A Day (Benzinga) +5.83%
08:00AM	Adaptimmune Enhances Its Pipeline of Wholly Owned Cell Therapies for Cancer with Transfer of PRAME and NY-ESO Target Programs from GSK (Newsfile)
Sep-09-22 10:23AM	Adaptimmune's Cancer Candidate Shows 44% Response Rate In Pretreated Ovarian, Urothelial, Head & Neck Cancers (Benzinga) -5.88%
07:00AM	Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors (Newsfile)
Aug-25-22 08:00AM	Adaptimmune to Host Live, Virtual Event to Review Phase 1 SURPASS Trial Data and Outline Plans for Further Development in SURPASS Family of Trials (Newsfile)
Aug-10-22 06:27AM	Analysts Have Just Cut Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Revenue Estimates By 25% (Simply Wall St.)
Aug-04-22 07:30AM	Adaptimmune Reports Second-Quarter Financial Results and Business Update (Newsfile) +19.59%
Aug-01-22 06:21AM	Shareholders in Adaptimmune Therapeutics (NASDAQ:ADAP) are in the red if they invested five years ago (Simply Wall St.) -5.95%
Jul-21-22 08:00AM	Adaptimmune to Report Q2 2022 Financial Results and Business Updates on Thursday, August 4, 2022 (Newsfile)
Jul-01-22 04:45PM	Got $500? 3 Absurdly Cheap Healthcare Stocks That Are Set to Skyrocket (Motley Fool)
11:10AM	What Kind Of Investors Own Most Of Adaptimmune Therapeutics plc (NASDAQ:ADAP)? (Simply Wall St.)
Jun-27-22 03:27PM	Why Adaptimmune Therapeutics Stock Is Popping Today (Motley Fool)
Jun-01-22 10:17AM	We're Not Worried About Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn (Simply Wall St.)
May-26-22 05:00PM	Clinical Responses Reported across Patient Subgroups with Adaptimmune's Cell Therapy, Afami-cel, Confirming Potential for People with Rare Sarcomas - BLA Submission On-Track (Newsfile)
May-17-22 05:03PM	Why Shares of Adaptimmune Therapeutics Rose 13.4% on Tuesday (Motley Fool) +10.56%
May-16-22 05:00PM	Preclinical Proof-of-Concept Data Supporting Future Clinical Development of Two New Cell Therapies Being Presented by Adaptimmune at ASGCT (GlobeNewswire)

Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. Its clinical pipeline includes Afami-cel, Lete-cel, and ADP-A2M4CD8. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rawcliffe Adrian	Chief Executive Officer	Jan 17 '24	Sale	0.67	30,080	20,244	44,848	Jan 17 05:31 PM
Bertrand William C JR	Chief Operating Officer	Jan 17 '24	Sale	0.67	18,908	12,725	7,785	Jan 17 05:30 PM
Norry Elliot	Chief Medical Officer	Jan 17 '24	Sale	0.67	18,276	12,300	7,785	Jan 17 05:31 PM
Lunger John	Chief Patient Supply Officer	Jan 17 '24	Sale	0.67	18,114	12,191	7,785	Jan 17 05:30 PM
Rawcliffe Adrian	Chief Executive Officer	Jan 16 '24	Sale	0.79	9,304	7,350	14,104	Jan 17 05:31 PM
Lunger John	Chief Patient Supply Officer	Jan 16 '24	Sale	0.79	4,681	3,698	7,023	Jan 17 05:30 PM
Bertrand William C JR	Chief Operating Officer	Jan 16 '24	Sale	0.79	4,681	3,698	7,023	Jan 17 05:30 PM
Norry Elliot	Chief Medical Officer	Jan 16 '24	Sale	0.79	2,287	1,807	3,363	Jan 17 05:31 PM
Rawcliffe Adrian	Chief Executive Officer	Jan 12 '24	Sale	0.85	17,257	14,739	26,388	Jan 12 05:00 PM
Norry Elliot	Chief Medical Officer	Jan 12 '24	Sale	0.85	7,799	6,661	11,841	Jan 12 05:00 PM
Bertrand William C JR	Chief Operating Officer	Jan 12 '24	Sale	0.85	5,220	4,458	7,874	Jan 12 05:00 PM
Lunger John	Chief Patient Supply Officer	Jan 12 '24	Sale	0.85	5,220	4,458	7,874	Jan 12 05:00 PM
Rawcliffe Adrian	Chief Executive Officer	Jan 11 '24	Sale	0.84	11,945	9,994	18,395	Jan 12 05:00 PM
Lunger John	Chief Patient Supply Officer	Jan 11 '24	Sale	0.84	4,009	3,354	6,104	Jan 12 05:00 PM
Bertrand William C JR	Chief Operating Officer	Jan 11 '24	Sale	0.84	4,009	3,354	6,104	Jan 12 05:00 PM
Norry Elliot	Chief Medical Officer	Jan 11 '24	Sale	0.84	4,009	3,354	6,104	Jan 12 05:00 PM
Rawcliffe Adrian	Chief Executive Officer	Sep 01 '23	Sale	0.78	2,403	1,874	3,449	Sep 01 07:00 PM
Lunger John	Chief Patient Supply Officer	Aug 01 '23	Sale	0.91	3,096	2,804	4,718	Aug 01 05:00 PM
Menzel Garry E	Director	Jul 10 '23	Sale	0.91	47,702	43,447	75,056	Jul 10 05:01 PM
Rawcliffe Adrian	Chief Executive Officer	Jun 27 '23	Sale	0.92	2,333	2,146	3,519	Jun 27 09:15 PM

Open in Screener

LQDA

Liquidia Corp

Apr 19 • 12:57PM ET

13.59

Dollar change -0.22
Percentage change -1.59	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWO DWAS VTWO PTH VHT IWN IWC

Index	RUT	P/E	-	EPS (ttm)	-1.21	Insider Own	26.75%	Shs Outstand	68.63M	Perf Week	-2.58%
Market Cap	1.03B	Forward P/E	-	EPS next Y	-0.53	Insider Trans	7.67%	Shs Float	55.69M	Perf Month	-14.53%
Income	-78.50M	PEG	-	EPS next Q	-0.32	Inst Own	47.14%	Short Float	13.34%	Perf Quarter	5.43%
Sales	17.49M	P/S	59.08	EPS this Y	5.30%	Inst Trans	-4.06%	Short Ratio	8.39	Perf Half Y	131.91%
Book/sh	0.69	P/B	19.72	EPS next Y	54.07%	ROA	-62.36%	Short Interest	7.43M	Perf Year	94.14%
Cash/sh	1.10	P/C	12.35	EPS next 5Y	-	ROE	-114.01%	52W Range	5.71 - 16.99	Perf YTD	12.97%
Dividend Est.	-	P/FCF	-	EPS past 5Y	30.44%	ROI	-158.09%	52W High	-20.01%	Beta	0.22
Dividend TTM	-	Quick Ratio	4.85	Sales past 5Y	423.30%	Gross Margin	76.18%	52W Low	138.00%	ATR (14)	0.75
Dividend Ex-Date	-	Current Ratio	4.85	EPS Y/Y TTM	-73.00%	Oper. Margin	-419.62%	RSI (14)	39.31	Volatility	5.80% 5.16%
Employees	136	Debt/Eq	0.07	Sales Y/Y TTM	9.75%	Profit Margin	-448.89%	Recom	1.57	Target Price	23.86
Option/Short	Yes / Yes	LT Debt/Eq	0.05	EPS Q/Q	-314.22%	Payout	-	Rel Volume	0.43	Prev Close	13.81
Sales Surprise	-4.30%	EPS Surprise	-81.66%	Sales Q/Q	-15.47%	Earnings	Mar 13 BMO	Avg Volume	885.56K	Price	13.59
SMA20	-9.45%	SMA50	-7.77%	SMA200	39.14%	Trades		Volume	212,396	Change	-1.59%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-05-24	Reiterated	Needham	Buy	$18 → $28
Sep-19-22	Resumed	Wedbush	Underperform	$3
Sep-01-22	Downgrade	Wedbush	Neutral → Underperform	$3
Jul-22-22	Initiated	Ladenburg Thalmann	Buy	$15
May-31-22	Initiated	BTIG Research	Buy	$14
May-26-22	Initiated	BofA Securities	Buy	$12
Dec-04-20	Initiated	H.C. Wainwright	Buy	$6
Nov-20-20	Downgrade	Wedbush	Outperform → Neutral	$20 → $4
Nov-08-18	Resumed	Jefferies	Buy
Sep-05-18	Initiated	Wedbush	Outperform	$26
Aug-20-18	Initiated	Needham	Buy	$30
Aug-20-18	Initiated	Jefferies	Buy	$22

Show Previous Ratings

Apr-02-24 09:00AM	Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-01-24 06:00AM	Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA (treprostinil) inhalation powder (GlobeNewswire)
Mar-20-24 01:50AM	Chief Medical Officer Rajeev Saggar Sells Shares of Liquidia Corp (LQDA) (GuruFocus.com)
01:49AM	Insider Sell: CFO and COO Michael Kaseta Sells 12,166 Shares of Liquidia Corp (LQDA) (GuruFocus.com)
Mar-16-24 02:42PM	Liquidia Corporation (NASDAQ:LQDA) Q4 2023 Earnings Call Transcript (Insider Monkey)
10:54PM	Loading…
Mar-13-24 10:54PM	Q4 2023 Liquidia Corp Earnings Call (Thomson Reuters StreetEvents) +5.36%
07:31AM	Liquidia Corp (LQDA) Reports Full Year 2023 Financial Results (GuruFocus.com)
07:10AM	Liquidia Technologies, Inc. (LQDA) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
06:00AM	Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-06-24 06:30AM	Liquidia Corporation to Report Full Year 2023 Financial Results on Wednesday, March 13, 2024 (GlobeNewswire)
Feb-21-24 03:17PM	United Therapeutics' Challenges FDA Over Liquidia's Drug Approval Process, Clocks Strong Q4 Earnings (Benzinga)
06:51AM	UPDATE 3-United Therapeutics starts litigation with FDA over rival Liquidia's drug application (Reuters)
06:24AM	United Therapeutics, in unusual step, sues FDA over rivals drug application (BioPharma Dive)
Jan-30-24 06:30AM	Liquidia Corporation Announces Poster Presentation at the Pulmonary Vascular Research Institute 2024 Annual Congress (GlobeNewswire)
Jan-29-24 09:55AM	Wall Street Analysts Think Liquidia Technologies, Inc. (LQDA) Could Surge 71.41%: Read This Before Placing a Bet (Zacks)
06:25AM	Loading…
Jan-25-24 06:25AM	UPDATE 1-US FDA still reviewing Liquidia's inhaled blood pressure drug (Reuters)
06:00AM	Liquidia Corporation Provides Update on New Drug Application for YUTREPIA (treprostinil) inhalation powder (GlobeNewswire)
Jan-19-24 06:30AM	Liquidia Corporation Announces Updates to Operations Leadership (GlobeNewswire)
Jan-09-24 06:21PM	Wall Street Analysts Believe Liquidia Technologies, Inc. (LQDA) Could Rally 29.94%: Here's is How to Trade (Zacks)
04:56PM	What Makes Liquidia Technologies, Inc. (LQDA) a Strong Momentum Stock: Buy Now? (Zacks)
Jan-08-24 08:22AM	Liquidia Corporation Files Response to United Therapeutics Lawsuit and Files Counterclaims (GlobeNewswire)
Jan-05-24 06:45AM	Liquidia Provides Update on Clinical Pipeline Targeting PAH and PH-ILD (GlobeNewswire)
Jan-04-24 09:10AM	Liquidia Corporation Announces $100 Million in New Financings (GlobeNewswire) +7.97%
Jan-02-24 06:45AM	Liquidia Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-29-23 06:45AM	16 Most Promising Long-Term Stocks According to Analysts (Insider Monkey)
Dec-25-23 08:00AM	Biotech CEOs Are Buying Up Their Surging Stocks (Barrons.com)
Dec-22-23 06:35PM	Peabody Energy, Janus International, and More Stocks See Action From Activist Investors (Barrons.com)
Dec-20-23 04:56PM	U.S. Federal Circuit Affirms Earlier PTAB Decision to Invalidate All Claims of United Therapeutics Patent No. 10,716,793 ('793 Patent) (GlobeNewswire) +35.70%
Dec-19-23 01:02PM	Insider Sell Alert: Chief Medical Officer Rajeev Saggar Sells 14,887 Shares of Liquidia Corp (LQDA) (GuruFocus.com) +5.63%
Dec-12-23 07:13AM	Liquidia Announces Pricing of Public Offering of Common Stock (GlobeNewswire)
10:47AM	Loading…
Nov-08-23 10:47AM	Liquidia Corporation (NASDAQ:LQDA) Q3 2023 Earnings Call Transcript (Insider Monkey)
12:44AM	Q3 2023 Liquidia Corp Earnings Call (Thomson Reuters StreetEvents)
Nov-07-23 07:07AM	Liquidia Corp (LQDA) Reports Q3 2023 Financial Results (GuruFocus.com)
06:30AM	Liquidia Corporation Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-31-23 06:30AM	Liquidia Corporation to Report Third Quarter 2023 Financial Results on November 7, 2023 (GlobeNewswire)
Oct-02-23 07:00AM	Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors (GlobeNewswire)
Sep-25-23 04:09PM	FDA Accepts Submission to Add PH-ILD to YUTREPIA Label (GlobeNewswire)
Sep-06-23 04:30PM	United Therapeutics Corporation Files Lawsuit Alleging Infringement of Tyvaso Patent Already Found to Be Invalid by U.S. Patent Office (GlobeNewswire)
Aug-13-23 05:22AM	Liquidia Corporation (NASDAQ:LQDA) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-11-23 12:38AM	Q2 2023 Liquidia Corp Earnings Call (Thomson Reuters StreetEvents) -9.13%
Aug-10-23 07:15AM	Liquidia Technologies, Inc. (LQDA) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
06:00AM	Liquidia Corporation Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-03-23 08:17AM	Liquidia Corporation to Report Second Quarter 2023 Financial Results on August 10, 2023 (GlobeNewswire)
Jul-27-23 09:13AM	Liquidia Stock Down 12% But Insiders Still In US$74k Profit (Simply Wall St.)
06:00AM	Liquidia Submits Amendment to Add PH-ILD Indication to Tentatively Approved NDA for YUTREPIA (treprostinil) Inhalation Powder (GlobeNewswire)
Jul-25-23 02:37PM	Liquidia stock drops after setback in United Therapeutics dispute (American City Business Journals)
08:25AM	Silver Spring's United Therapeutics claims victory in patent infringement suit against Liquidia (American City Business Journals)
Jul-24-23 01:46PM	U.S. Federal Circuit Affirms All District Court Rulings in Patent Litigation (GlobeNewswire) -12.76%
Jun-29-23 11:24AM	Liquidia (LQDA) Up on Deal With Pharmosa to Co-Develop PH Drug (Zacks) -17.68%
Jun-28-23 05:36AM	Liquidia Corporation and Pharmosa Biopharm Announce Collaboration for Sustained-Release Inhaled Treprostinil Product in North America (GlobeNewswire) +10.99%
May-31-23 06:30AM	Liquidia Corporation to Present at the 2023 Jefferies Healthcare Conference (GlobeNewswire)
May-30-23 11:26AM	Investing in Liquidia (NASDAQ:LQDA) a year ago would have delivered you a 106% gain (Simply Wall St.)
May-21-23 03:39PM	Hero or Zero? 7 High-Risk Stocks to Make You Rich Or Broke. (InvestorPlace)
May-19-23 06:15AM	Liquidia Announces Poster Presentation at the 2023 American Thoracic Society International Conference (GlobeNewswire) +6.14%
May-09-23 06:33AM	Institutional investors are Liquidia Corporation's (NASDAQ:LQDA) biggest bettors and were rewarded after last week's US$60m market cap gain (Simply Wall St.)
May-04-23 09:15AM	Liquidia Technologies, Inc. (LQDA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
06:30AM	Liquidia Corporation Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-02-23 06:45AM	Liquidia Corporation to Present at BofA Securities 2023 Health Care Conference (GlobeNewswire)
Apr-27-23 06:45AM	Liquidia Corporation to Report First Quarter 2023 Financial Results on May 4, 2023 (GlobeNewswire)
Apr-20-23 04:17AM	Strength Seen in EyePoint Pharmaceuticals (EYPT): Can Its 9.6% Jump Turn into More Strength? (Zacks)
Apr-18-23 08:33AM	Liquidia Corporation's (NASDAQ:LQDA) Earnings Haven't Escaped The Attention Of Investors (Simply Wall St.)
Apr-11-23 06:45AM	Liquidia Corporation to Present at 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-03-23 06:45AM	Liquidia and GSK Restructure License to PRINT Technology for Inhaled Applications (GlobeNewswire)
Mar-25-23 08:33AM	Industry Analysts Just Made A Captivating Upgrade To Their Liquidia Corporation (NASDAQ:LQDA) Revenue Forecasts (Simply Wall St.)
Mar-20-23 04:10AM	Liquidia Corporation (NASDAQ:LQDA) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-18-23 08:34AM	Liquidia Full Year 2022 Earnings: Beats Expectations (Simply Wall St.)
Mar-17-23 03:22AM	Q4 2022 Liquidia Corp Earnings Call (Thomson Reuters StreetEvents)
Mar-16-23 07:55AM	Liquidia Technologies, Inc. (LQDA) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +15.25%
06:30AM	Liquidia Corporation Reports Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-09-23 10:00AM	Liquidia Technologies, Inc. (LQDA) May Report Negative Earnings: Know the Trend Ahead of Q4 Release (Zacks) -5.41%
07:19AM	Liquidia Corporation to Report Full Year 2022 Financial Results on Thursday, March 16, 2023 (GlobeNewswire)
Feb-17-23 07:33AM	Insiders saw their US$2.6m investment bump up to US$4.2m after Liquidia Corporation (NASDAQ:LQDA) soared 15% last week (Simply Wall St.)
Feb-05-23 08:49PM	Decision moves Liquidia, United Therapeutics patent dispute toward resolution (American City Business Journals)
Feb-03-23 05:10AM	Strength Seen in Liquidia Technologies, Inc. (LQDA): Can Its 9.7% Jump Turn into More Strength? (Zacks)
Feb-02-23 04:39PM	Patent Trial and Appeal Board (PTAB) Reaffirms Decision to Invalidate All Claims of United Therapeutics (UTHR) Patent No. 10,716,793 (793 Patent) (GlobeNewswire) +9.70%
06:30AM	Liquidia Corporation Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-09-23 10:01PM	Liquidia inks $100M financing agreement amid patent dispute (American City Business Journals)
06:30AM	Liquidia Enters Into a Revenue Interest Financing Agreement With HealthCare Royalty for Up to $100 Million (GlobeNewswire)
Dec-30-22 09:40AM	Are Medical Stocks Lagging Assertio (ASRT) This Year? (Zacks)
Dec-14-22 09:40AM	Are Medical Stocks Lagging Assertio (ASRT) This Year? (Zacks)
Dec-05-22 04:05PM	Liquidia Announces Collaboration to Develop a New Infusion Pump for Subcutaneous Delivery of Treprostinil Injection to Treat Pulmonary Arterial Hypertension (PAH) (GlobeNewswire) -5.65%
Dec-01-22 09:55AM	Wall Street Analysts Think Liquidia Technologies, Inc. (LQDA) Could Surge 153%: Read This Before Placing a Bet (Zacks) +5.78%
Nov-28-22 09:40AM	Is Liquidia Technologies (LQDA) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-08-22 07:45AM	Liquidia Technologies, Inc. (LQDA) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
06:30AM	Liquidia Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-02-22 10:15AM	ANAVASI DIAGNOSTICS ANNOUNCES NEWLY ELECTED OUTSIDE BOARD OF DIRECTORS (PR Newswire)
Nov-01-22 06:45AM	Liquidia to Report Third Quarter 2022 Financial Results on November 8, 2022 (GlobeNewswire) +5.93%
Oct-27-22 04:10PM	Precedential Opinion Panel Denies United Therapeutics Request for Review of 793 Inter Partes Review Decision (GlobeNewswire)
Oct-26-22 09:40AM	Are Medical Stocks Lagging Acadia Healthcare (ACHC) This Year? (Zacks)
Oct-17-22 06:30AM	Liquidia Announces Presentations at the CHEST 2022 Annual Meeting (GlobeNewswire)
Sep-26-22 06:45AM	7 Momentum Stocks to Buy Now for Extraordinary Gains (InvestorPlace)
Sep-10-22 08:24AM	Trade Alert: The CEO & Director Of Liquidia Corporation (NASDAQ:LQDA), Roger Jeffs, Has Just Spent US$244k Buying 2.6% More Shares (Simply Wall St.)
Sep-08-22 11:26AM	Liquidia (NASDAQ:LQDA) Is Using Debt Safely (Simply Wall St.) +5.87%
Sep-06-22 12:15PM	Liquidia faces delay for drug launch after ruling in United Therapeutics case (American City Business Journals)
Sep-02-22 05:58PM	Why Liquidia Stock Rocketed Nearly 21% Higher Today (Motley Fool) +20.58%
Aug-31-22 07:46PM	Liquidia Provides Update on Hatch-Waxman Litigation and to Host Call on September 1, 2022, at 8:00am E.T. (GlobeNewswire) +7.25%
09:55AM	Wall Street Analysts Believe Liquidia Technologies, Inc. (LQDA) Could Rally 136%: Here's is How to Trade (Zacks)
09:40AM	Is Liquidia Technologies (LQDA) Outperforming Other Medical Stocks This Year? (Zacks)
Aug-23-22 03:09PM	Find Highly-Ranked Cheap Stocks Under $10 to Buy with this Screen (Zacks)
12:00PM	Here's Why Liquidia Technologies, Inc. (LQDA) is a Great Momentum Stock to Buy (Zacks)

Liquidia Corp. operates as a holding company which through its subsidiary engages in developing and commercializing biopharmaceutical products. It engages in novel products development used in PRINT technology to transform the lives of patients. The company was founded on June 28, 2020, and is headquartered in Morrisville, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
JEFFS ROGER	Chief Executive Officer	Apr 12 '24	Sale	14.58	8,360	121,889	826,985	Apr 16 05:15 PM
Kaseta Michael	CFO and COO	Apr 12 '24	Sale	14.58	3,136	45,723	315,045	Apr 16 05:16 PM
Schundler Russell	General Counsel	Apr 12 '24	Sale	14.58	2,060	30,035	486,027	Apr 16 05:17 PM
Moomaw Scott	Chief Commercial Officer	Apr 12 '24	Sale	14.58	1,585	23,109	151,881	Apr 16 05:16 PM
Saggar Rajeev	Chief Medical Officer	Apr 12 '24	Sale	14.58	1,525	22,234	213,321	Apr 16 05:17 PM
Adair Jason	Chief Business Officer	Apr 12 '24	Sale	14.58	1,189	17,336	111,537	Apr 15 08:31 PM
JEFFS ROGER	Chief Executive Officer	Mar 18 '24	Sale	15.82	28,583	452,183	835,345	Mar 19 09:46 PM
Kaseta Michael	CFO and COO	Mar 18 '24	Sale	15.82	12,166	192,466	318,181	Mar 19 09:47 PM
Schundler Russell	General Counsel	Mar 18 '24	Sale	15.82	8,653	136,890	488,087	Mar 19 09:48 PM
Saggar Rajeev	Chief Medical Officer	Mar 18 '24	Sale	15.82	7,530	119,125	214,846	Mar 19 09:46 PM
Moomaw Scott	Chief Commercial Officer	Mar 18 '24	Sale	15.82	6,108	96,629	153,466	Mar 19 09:47 PM
Adair Jason	Chief Business Officer	Mar 18 '24	Sale	15.81	4,657	73,649	108,640	Mar 19 09:50 PM
Moomaw Scott	Chief Commercial Officer	Feb 29 '24	Sale	14.17	546	7,737	159,574	Mar 04 07:07 PM
Adair Jason	Chief Business Officer	Feb 29 '24	Sale	14.17	455	6,447	97,412	Mar 04 07:05 PM
Adair Jason	Chief Business Officer	Dec 18 '23	Sale	7.70	77	593	54,932	Dec 20 05:20 PM
Caligan Partners LP	Director	Dec 14 '23	Buy	7.16	1,117,318	7,999,997	11,280,945	Dec 14 04:42 PM
Manning Paul B	Director	Dec 14 '23	Buy	7.16	279,330	2,000,003	279,330	Dec 18 05:00 PM
JEFFS ROGER	Chief Executive Officer	Dec 14 '23	Buy	7.16	139,665	1,000,001	640,805	Dec 18 05:02 PM
Moomaw Scott	Chief Commercial Officer	Nov 30 '23	Sale	7.28	542	3,946	106,737	Dec 05 09:18 PM
Lippe Robert A	Chief Operations Officer	Nov 30 '23	Sale	7.28	497	3,618	193,788	Dec 05 09:21 PM
Adair Jason	Chief Business Officer	Nov 30 '23	Sale	7.28	452	3,291	54,478	Dec 05 09:15 PM
Adair Jason	Chief Business Officer	Sep 19 '23	Sale	6.51	75	488	53,637	Sep 20 06:14 PM
Moomaw Scott	Chief Commercial Officer	Aug 31 '23	Sale	6.88	537	3,695	105,404	Sep 05 08:10 PM
Lippe Robert A	Chief Operations Officer	Aug 31 '23	Sale	6.88	505	3,474	192,567	Sep 05 08:11 PM
Adair Jason	Chief Business Officer	Aug 31 '23	Sale	6.88	445	3,062	53,452	Sep 05 08:09 PM
Moomaw Scott	Chief Commercial Officer	May 31 '23	Sale	8.08	651	5,260	102,268	Jun 02 05:05 PM
Lippe Robert A	Chief Operations Officer	May 31 '23	Sale	8.08	597	4,824	189,646	Jun 02 05:03 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

NET

Cloudflare Inc

ADAP

Adaptimmune Therapeutics Plc ADR

LQDA

Liquidia Corp

Upgrade your FINVIZ experience